Clinical Trial Update: The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating chidamide + decitabine + camrelizumab versus decitabine + camrelizumab in anti-PD-1 resistant classical Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• Chidamide (chidamide)
• Decitabine (Decitabine)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Hodgkin Lymphoma, Anti-PD-1 Antibody Resistant | Phase 2 | Status: UNKNOWN